Buscar resultados de ensayos clínicos
Lymphoma, T-Cell, Peripheral - 25 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma Condición: Peripheral T-Cell Lymphoma Fecha: 2013-02-25 Intervenciones: Drug: Alemtuzumab Consolidation after CHOP induction |
Completed |
Nombre del estudio: Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma Condición: Peripheral T-Cell Lymphoma Fecha: 2005-08-26 Intervenciones: Drug: Velcade + ACVBP regimen |
Active, not recruiting |
Nombre del estudio: A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma Condición: Peripheral T-cell Lymphoma Fecha: 2007-01-23 Intervenciones: Drug: Romidepsin Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-d |
Active, not recruiting |
Nombre del estudio: Alemtuzumab and CHOP in T-cell Lymphoma Condición: Lymphoma, T-Cell, Peripheral Fecha: 2008-02-14 Intervenciones:
|
Completed |
Nombre del estudio: Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) Condición: Peripheral T-Cell Lymphoma Fecha: 2012-05-30 Intervenciones: Biological: KW-0761 (mogamulizumab) 1 mg/kg administered intravenously weekly x 4 then every other week |
Not yet recruiting |
Nombre del estudio: Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients Condición: Peripheral T-cell Lymphoma Fecha: 2016-06-17 Intervenciones:
|
Terminated |
Nombre del estudio: Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Condición: Peripheral T-Cell Lymphoma Fecha: 2013-04-24 Intervenciones: Drug: Brentuximab vedotin Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day |
Completed |
Nombre del estudio: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Condición: Peripheral T-cell Lymphoma Fecha: 2009-03-19 Intervenciones: Drug: PXD101 Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of e |
Recruiting |
Nombre del estudio: GDP in Frontline Chemotherapy for Patients With PTCL-NOS Condición: Lymphoma, T-Cell, Peripheral Fecha: 2015-03-26 Intervenciones: Drug: GDP chemotherapy gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin |
Completed |
Nombre del estudio: Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condición: Peripheral T-cell Lymphoma Fecha: 2006-08-14 Intervenciones: Drug: Pralatrexate Injection Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week |